Adverum Biotechnologies to Present at Upcoming Investor Conferences

Rhea-AI Summary

Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focusing on gene therapy for ocular diseases, announced CEO Laurent Fischer will present at two investor conferences in March 2023. The first is the Cowen 43rd Annual Health Care Conference on March 8 at 12:50 p.m. ET, followed by the Oppenheimer 33rd Virtual Annual Healthcare Conference on March 15 at 2:00 p.m. ET. Investors can access a replay of the webcast for 90 days post-presentation on the company's website. Adverum aims to redefine treatment for ocular diseases with its novel gene therapy candidate, ixoberogene soroparvovec, which could provide a one-time injection solution for wet age-related macular degeneration.

REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:

• Cowen 43^rd Annual Health Care Conference on Wednesday, March 8, 2023 at 12:50 p.m. ET
• Oppenheimer 33^rd Virtual Annual Healthcare Conference on Wednesday, March 15, 2023 at 2:00 p.m. ET

The on-demand webcast corporate presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for 90 days following the presentation.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.

Corporate, Investor and Media Inquiries

Anand Reddi
Vice President, Head of Corporate Strategy, External Affairs and Engagement
Adverum Biotechnologies, Inc.
T: 650-649-1358
E: areddi@adverum.com 

FAQ

When is Laurent Fischer presenting at the Cowen Conference for Adverum (ADVM)?

Laurent Fischer will present at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 12:50 p.m. ET.

What is the focus of Adverum Biotechnologies as mentioned in the press release?

Adverum Biotechnologies focuses on establishing gene therapy as a new standard of care for prevalent ocular diseases.

When will Adverum (ADVM) present at the Oppenheimer Conference?

Adverum will present at the Oppenheimer 33rd Virtual Annual Healthcare Conference on March 15, 2023, at 2:00 p.m. ET.

What is ixoberogene soroparvovec (Ixo-vec) developed by Adverum (ADVM)?

Ixoberogene soroparvovec is a novel gene therapy candidate developed for a one-time injection treatment for wet age-related macular degeneration.

How can investors access Adverum's conference presentation?

Investors can access the on-demand webcast of Adverum's presentation on their Investors website, available for 90 days after the event.